Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
The Zacks Analyst Blog Highlights: Amazon, Apple, Gilead Sciences, Amgen and Visa
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Apple, Gilead Sciences, Amgen and Visa
ETF Asset Report of Coronavirus-Inflicted April
by Sanghamitra Saha
These ETF areas have gained or lost assets in the month of April.
5 Top-Performing ETF Areas of April That Are Up At Least 25%
by Sanghamitra Saha
These ETF areas showered gains in the lockdown-infected April.
Amazon Misses on Earnings, Apple Beats but Trades Lower
by Mark Vickery
Amazon came in well below earnings estimates, Apple beats on both top & bottom, plus results from Gilead, Amgen and Visa.
Gilead Sciences (GILD) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 6.33% and 2.61%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Biotech ETFs Gain on New Positive Data for Gilead's Remdesivir
by Sweta Jaiswal, FRM
As the coronavirus continues to spread, the latest positive data on remdesivir is some relief in such challenging times.
The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences
Stock Market News for Apr 30, 2020
by Zacks Equity Research
U.S. stocks closed sharply higher on Wednesday following positive clinical trial data of a drug for potential coronavirus treatment.
Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat
by Ritujay Ghosh
A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.
5 Small-Cap ETFs Beating S&P 500 in April
by Sanghamitra Saha
Extension of the paycheck protection program, some forgivable loans, strong dollar and the talks of reopening of the economy supported the small-cap ETFs in April.
Leveraged Small-Cap and Inverse Leveraged Gold Miners: 2 ETFs to Watch on Outsized Volume
by Sanghamitra Saha
URTY and JDST have seen elevated trading volume on Wednesday.
Should You Buy Gilead Sciences (GILD) Ahead of Earnings?
by Zacks Equity Research
Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Gilead's Coronavirus Drug Shows Positive Data
by Zacks Equity Research
Gilead's Coronavirus Drug Shows Positive Data
Positive Data for Gilead's (GILD) Remdesivir; Plus Q1 for BA, GE
by Mark Vickery
This is obviously remarkably good news for COVID-19 suffers, the general public in the throes of this pandemic, and of course Gilead itself.
Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More
by Zacks Equity Research
Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.
Top Stock Research Reports for Cisco, Abbott, NextEra & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Abbott Laboratories (ABT) and NextEra Energy (NEE).
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Amgen's (AMGN) performance when it reports first-quarter results.
First-Mover Pandemic Disease Fight ETF On The Way
by Sweta Killa
Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.
Will Strong HIV Sales Drive Gilead's (GILD) Q1 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on the experimental coronavirus treatment when Gilead (GILD) reports first-quarter 2020 results.
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
Focus on Coronavirus Treatments to Boost Biotech Stocks
by Zacks Equity Research
With the coronavirus pandemic raging on, biotech companies are in focus as they are racing against time to evaluate every possible therapy to combat the spread.
Equities See Modest Declines as Many Businesses Prepare to Reopen
by David Borun
A reduction in Coronavirus cases and public outcry have many states planning a resumption of business activities.
Ride Out the Coronavirus Mayhem With These ETF Areas
by Sweta Jaiswal, FRM
We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.
Ride Out the Coronavirus Mayhem With These ETF Areas
by Sweta Jaiswal, FRM
We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.